Follicular lymphomas are currently subdivided into grades I, II, IIIa and IIIb. This distinction is, however, questioned.
Introduction
Follicular lymphoma (FL) is the commonest form of indolent lymphoid tumor and the second most frequent histotype of non-Hodgkin's lymphoma (NHL) in western countries. 1 Neoplastic cells resemble centroblasts and centrocytes of normal germinal centers and show a growth pattern that may be follicular (>70%), follicular and diffuse (25%) or diffuse (<5%). Based on the amount of centroblasts, FL is usually classified as grade (G) I, II, IIIa and IIIb. 1 Even though the criterion for this classification appears objective, grading has a notoriously poor reproducibility among community pathologists as well as experienced hematopathologists (agreement 61%-73%). 2 This reflects the variability of the field width among different high power objectives (i.e. x40), as well as the difficulties sometimes encountered in assessing the exact number of centroblasts due to the occurrence of large centrocytes and small centroblasts. Thus, the rationale for FL grading is still matter of debate. Interestingly, according to morphology, phenotype and genetic features (i. e. the presence of ongoing immunoglobulin somatic hypermutations) FL is currently supposed to derive from germinal center B cells, although no data are available in this respect as regards the global molecular profile.
FL typically has an indolent course, with the median survival of affected patients being 7 years, but is virtually incurable with conventional therapies. Furthermore, 25-60% of cases may transform into an aggressive diffuse large B-cell lymphoma (DLBCL), with a very poor prognosis. 1 Though the International Prognostic Index (recently specifically modified for FL) is of some use, to date there are no reliable markers of risk of transformation or factors predictive of response to therapy and survival; furthermore, the molecular mechanisms leading to drug resistance and transformation are not well known. 6 Recently, gene expression studies showed that clinical aggressiveness can be associated with specific molecular signatures partially independent from histological grade 7 and that immune reactive cells can play a major role in determining the outcome. 8 Subsequently, the role of non-neoplastic components was also highlighted by independent tissue microarray analyses. [9] [10] [11] However, to date, gene expression studies have shown that clinical aggressiveness is possibly dependent on reactive non-neoplastic components, but have not provided a molecular rationale for histological grading 7, 8 and it is still debated whether FL GIIIb should truly be considered a FL or whether it should be included within DLBCL.
In this study, we performed a gene expression analysis of 43 FL, 50 B-NHL of different types, and 20 samples of normal B-lymphocytes in order to assess: (i) the relationship of FL with normal B cells and other B-cell malignancies; (ii) whether FL is a unique disease; and (iii) whether FL GIIIb should be considered within the frame of FL or DLBCL.
Design and Methods

Case selection
Forty-three cases of FL were studied. In 37 cases, cryopreserved tissue blocks were used and in the other six cases enriched neoplastic cells. 12 The diagnosis and grading of FL was made according to the World Health Organization (WHO) classification by four experienced hematopathologists (CA, SS, BF and SAP). Notably, the four examples of GIIIb FL showed a pure follicular growth pattern and positivity for BCL2. All the samples were obtained at the time of diagnosis, before administration of treatment. The clinical and histopathological characteristics of the 37 FL cases for which whole genome profiling was performed are summarized in Table 1 . In addition, samples of normal B-cell subpopulations including centroblasts (n=5), centrocytes (n=5), naïve cells (n=5), and memory cells (n=5) were studied. 13 Finally, a panel of B-NHL including Burkitt's lymphoma (BL, n=4), DLBCL (n=16), mantle cell lymphoma (MCL, n=10), hairy cell leukemia (HCL, n=10), and B-cell chronic lymphocytic leukemia (B-CLL, n=10) were studied. Of note, the samples of these cases (excluding the HCL) consisted of enriched neoplastic cells. Details on their characteristics have been reported previously. 12, 14 Finally, in silico data concerning 37 cases of germinal center B-cell type (GCB) DLBCL were retrieved from URL http://www.ncbi.nlm.nih.gov/-projects/geo/. 15 These cases were randomly selected from among those with a diagnosis of GCB-DLBCL (as we could show a consistent relation of FL with germinal center cells) and no MYC rearrangements or the molecular signature of BL. For proper comparison with our samples, gene expression values were normalized per gene and per chip. In addition, analysis of control genes revealed no significant differences between the two series.
Informed consent to these studies was obtained from all the enrolled patients and the tissue collection was approved by each institutional ethical committee.
Gene expression analysis
Gene expression profiles were generated and analyzed as previously reported 12, 14, 16 (for details, see the online Supplementary appendix). Gene expression studies were conduced according to MIAMI guidelines. Raw gene expression data will be available at http://www.ncbi.nlm.nih.gov/projects/geo/ (accession number GSE6338).
Results
Relationship between follicular lymphoma, normal B cells and other B-cell malignancies
We first performed an unsupervised analysis and studied normal B cells (n=20) and cases of FL (n=6), BL (n=4), DLBCL (n=16), MCL (n=10), B-CLL (n=10) and HCL (n=10). According to the global gene expression profile FL turned out to be clearly distinct from other Bcell derived malignancies (Online Supplementary Figure  S1 ). As expected, FL was closer to germinal center related B-NHL (BL and DLBCL) than to tumors more related to naive or memory B cells (MCL, B-CLL and HCL).
Secondly, in order to evaluate the relationship between FL and normal B cells we applied a molecular classifier previously used to identify possible counterparts of lymphoid neoplasia. 12, 13, 16 As expected, we found that FL has a gene expression profile closer to that of GC cells rather than to naive and memory B-cells ( Figure 1 ). However, according to the indolent behavior of the tumor, different from that of the other GC B-cell derived lymphomas (i.e. BL and GCB-DLBCL) and more similar to the one of post-GCB tumors (such as HCL), we found that many cellular programs are regulated in FL as in memory B cells ( Figure 1C , Online Supplementary  Table S1 ). Comparable results were obtained when analyzing enriched neoplastic cells from patients with FL ( Figure 1 ) or frozen lymph-nodes (not shown). As a clear differentiation between centroblasts and centrocytes is still problematic, 13 it was not possible to definitely establish the origin of FL from these cells. Nevertheless, our analysis showed that FL is possibly closer to centrocytes rather than to centroblasts, independently of the grade (Online Supplementary Figure S2 ). Of note, even GIIIb cases, by definition constituted by a large cell population, appeared to be closer to centrocytes (Online Supplementary Figure S2) .
Details on gene profiling of normal B cells have been already reported. 13 
Follicular lymphoma is a single disease
We investigated whether FL is a unique entity or comprises discrete molecular subgroups. To address this issue, we used unsupervised hierarchical clustering to study the 37 cases of FL for which whole genome profiling was performed. We found that FL had a relatively homogeneous gene expression profile, independently of their grade (Figure 2A ). In particular, the GIIIb cases did not constitute a separate cluster but were scattered within the other cases (Figure 2A 
B C
supervised analysis (ANOVA test) -a stronger methodology for identifying molecular signatures of specific subgroups of samples -was applied, comparing FL of different histological grades (GI-II vs. GIIIa vs. GIIIb), a signature (30 genes) able to discriminate GIIIb forms was identified, whereas GI-II and GIIIa cases were still mixed up ( Figure 2B ) (Online Supplementary Table 2S ).
Grade IIIb folicular lymphoma is closer to folicular lymphoma than to diffuse large B-cell lymphoma
There have been some suggestions that GIIIb FL should be reclassified as DLBCL with follicular morphology. 17 We, therefore, investigated whether GIIIb FL is more related to GI-IIIa FL or to DLBCL. In order to address this issue, we first applied unsupervised hierarchical clustering to 37 FL and 37 GCB-DLBCL cases. We found that GIIIb FL are closer to other FL than to GCB-DLBCL, according to the global gene expression profiling as all the cases clustered within the FL group ( Figure 3A) . We then clustered the same cases on the basis of genes differentially expressed in FL (GIIIb excluded) and GCB-DLBCL -using either tissue samples or enriched casesand previously identified by supervised comparison (Online Supplementary Tables S3 and S4) . Again, GIIIb FL clustered within the other FL ( Figure 3B and Online Supplementary Figure S3A) . Finally, we generated a molecular signature distinguishing GIIIa FL and GCB-DLBCL by supervised analysis (268 genes, Online Supplementary  Table S5 ). According to the expression of these genes, GIIIb FL again appeared to be closer to FL rather than to DLBCL (Online Supplementary Figure S3B ).
Grade IIIa folicular lymphoma are closer to grade I-II rather than to grade IIIb folicular lymphoma
Whether GIIIa FL should be classified within GI-II FL or GIIIb FL is currently under debate. We, therefore, investigated at a molecular level whether GIIIa are closer to the former or to the latter based on gene expression profiling. To this end, we performed a hierarchical clustering of FL using a gene list obtained by supervised comparison of GI-II vs. GIIIb cases (Online Supplementary Table S6 ). We found that GIIIa tumors were definitely closer to the indolent forms, being scattered among them within the same cluster (Online Supplementary Figure S4A ). In addition, we applied a cell type classification method and confirmed that GIIIa FL are closer to GI-II FL than to GIIIb FL (Online Supplementary Figure S4B ).
Discussion
In this study, we performed a gene expression analysis of FL, normal B-cell subpopulations and a consistent panel of other B-NHL, and addressed specific issues of FL biology. First of all, we showed that although the global profile confirmed the relation of FL with germinal center B cells, many relevant programs were regulated as in resting (memory) B cells ( Figure 1C ), consistently with an indolent clinical behavior. To understand whether this phenomenon corresponds to an initial differentiation into memory cells or an aberrant malignant phenotype, further studies are needed. Secondly, we provide relevant information which could be useful for a future classification of FL. Cases of FL are currently subdivided into grades I, II, and III according to the number of large cells.
1 Different therapeutic approaches are sometimes applied to the indolent (GI-II) and aggressive (GIII) forms. 18 Furthermore, GIII FL are divided into GIIIa and GIIIb forms, although some authors consider Hierarchical clustering of 37 FL cases. The samples are clustered according to the expression of 30 genes which emerged from supervised analysis comparing GI-II vs. GIIIa vs. GIIIb (ANOVA test, one-way test with Bonferroni's correction for multiple testing and a family-wise error rate of 0.01). The dendrograms were generated using a hierarchical clustering algorithm based on the average-linkage method. In the matrix, each column represents a sample and each row represents a gene. The color scale bar shows the relative gene expression changes normalized by the standard deviation (0 is the mean expression level of a given gene). GIIIb constitute a discrete subgroup while GIIIa are scattered within GI-II cases. that the latter should be reclassified as DLBCL with follicular morphology. 17 Notably, GIIIb cases have also been reported to have peculiar clinical features. 19 In the last few years, FL have been studied by gene expression profiling by different groups. For example, de Jong et al. analyzed the molecular basis of clinical aggressiveness and an expression profile of 81 genes was established that could, with an accuracy of 100%, distinguish low-grade from high-grade disease. 10 In another study it was shown that non-neoplastic components are probably relevant to the clinical outcome, but the roles of single cellular populations could not be clearly defined even though macrophages appeared to be significantly involved. [8] [9] [10] 20, 21 In addition, the molecular basis of transformation to DLBCL has been extensively analyzed. [22] [23] [24] However, although important new elements for prognostication have been discovered and are currently being evaluated in a prospective manner, a molecular rationale for a FL classification had not been identified yet.
Our molecular analysis shows, for the first time, that the gene expression profile of FL is relatively homogeneous, independently of the histological grade ( Figure   2 ). However, we also found that GIIIb cases constitute a clearly distinct subgroup among FL ( Figure 2B ) and, most importantly, showed that they should be still considered as FL since they appeared to be closer to FL than to DLBCL (Figure 3 and Online Supplementary Figure S3) . Nevertheless, two out of four GIIIb cases clustered close to GCB-DLBCL, indicating the potential existence of similarities. Certainly, our observations warrant further validation in an independent context, given the limited number of GIIIb FL cases analyzed.
Interestingly, when looking for biological processes possibly regulated by genes belonging to the molecular signatures able to distinguish among FL with different histological grade (Online Supplementary Table S2 ), it appears that some categories, such as protein/macromolecule biosynthesis, metabolism, cellular morphogenesis, cell cycling and cell-growth and maintenance, are differentially expressed in GI-II vs. GIII tumors. However, no specific functional category can be found to be significantly over-represented in those signatures. On the other hand, at present, we cannot discriminate between FL GI-IIIa and FL GIIIb based on immunohistochemical markers. In conclusion, our molecular analysis showed that: (i) FL has a molecular profile distinct from other B-cell malignancies and consistently related to germinal center B cells; (ii) FL is a single disease; in particular, GI-IIIa FL tend to cluster together, with GIIIa being closer to GI-II FL than to GIIIb FL; and (iii) GIIIb FL cases constitute a distinct subgroup whose molecular signature is, nevertheless, more similar to that of the other FL than to that of GCB-DLBCL. Taken together, these data do not justify lumping FL GIIIb with DLBCL and support a possible revision of histological grading of FL, which might simply have two categories: FL and FL/large cell, corresponding to the present grades I-IIIa and IIIb, respectively. Further analyses on larger independent panels of cases are warranted.
Authorship and Disclosures
PP was responsible for the study design, gene expression analysis and drafting the article; UK, AC and YZ were responsible for gene expression generation and analysis; CA, BB, SS and FS were responsible for data and sample collection; EG was responsible for patients' care; BF took part in case selection and evaluation; PLZ was responsible for patients' care and funding; SAP was responsible for study design, drafting the article, and funding. The authors have no conflicting financial interests to declare.
